About Agent Capital

Investments That Matter

Agent Capital is a healthcare venture capital firm focused on investing in novel, differentiated therapeutics and treatments that address unmet patient needs.

From preclinical to commercial, we make direct equity investments across all stages of development.

Our team partners with scientists, entrepreneurs and other investors to develop the next generation of healthcare innovations, focusing on making a difference in patients’ lives.

Investment Team

Geeta Vemuri, PhD, MBA

Managing Partner, Founder

Geeta Vemuri, PhD, MBA

Managing Partner, Founder

Prior to Agent Capital, Dr. Vemuri was the Managing Partner of Baxter Ventures and the Managing Partner of Baxalta Ventures, where she led each corporate venture capital arm with more than $300M under management. Prior to Baxter, Dr. Vemuri was a Partner at Quaker Partners where she focused on biotech and healthcare investments. Dr. Vemuri has served on the board of a variety of companies, including Cempra (until its IPO and Dr. Vemuri’s departure in 2011), Covagen (acq. by J&J), Gadeta (acq. by Gilead), Naurex (acq. by Allergan), Ocular Therapeutix, Protez Pharmaceuticals (acq. by Novartis), Syntimmune (acq. by Alexion), and True North Therapeutics (acq. by Bioverativ/Sanofi), among others. Dr. Vemuri received a PhD in biochemistry from Indian Institute of Sciences and an MBA from The Wharton School at the University of Pennsylvania.

×

Jacopo Leonardi, MBA

General Partner

Jacopo Leonardi, MBA

General Partner

Jacopo is a proven global biopharmaceutical executive with a 25-year track record of creating sustainable growth for new ventures and underperforming franchises. He has deep expertise in multiple therapeutic areas including Orphan & Rare Diseases, Immunology, and Neurology and leading large teams in a range of functions including Strategy, Commercial Operations, R&D, Medical Affairs, Manufacturing, and Quality with a number of industry-leading biopharmaceutical companies, Eli Lilly, Johnson and Johnson, Baxter and Baxalta.

Prior to Agent Capital, Jacopo served on boards and in executive leadership across multiple companies in healthcare. As an Operating Partner at The Vistria Group, Jacopo was part of a team that acquired and helped accelerate the growth of AIS Healthcare, the nation’s leading 503A specialty pharmacy focused on targeted drug delivery and advanced infusion care in Neurology and Immunology. Jacopo serves as a Director on the AIS Board. Prior to his most recent healthcare ventures, Jacopo was Executive Vice President and President of Immunology for Baxalta where he led a fast growing $2.5B+ Global Division.

He was honored by the Healthcare Businesswomen’s Association (HBA) as the 2016 HBA Honorable Mentor of the Year for his dedication to the development and advancement of women in healthcare.

Jacopo received his MBA from Duke University’s Fuqua School of Business and Bachelor of Science from Rutgers College, where he was recognized as a Henry Rutgers Honors Scholar.

×

Preston Noon, PharmD, MBA

General Partner, Co-Founder

Preston Noon, PharmD, MBA

General Partner, Co-Founder

Prior to Agent Capital, Dr. Noon was at Baxalta Ventures where he supported new investment opportunities. Prior to Baxalta Ventures, Dr. Noon was a post-doctoral Associate for the U.S. Business Development and Licensing group of Bayer Pharmaceuticals, where he worked on in-licensing assets, acquisitions and asset divestitures. Prior to Bayer, Dr. Noon was an MBA analyst at Bristol-Myers Squibb for Global Medical Affairs. He began his career in the pharmaceutical industry working at Bristol-Myers Squibb to support clinical trial operations, specifically to monitor and improve enrollment timelines for oncology and immunology assets including ipilimumab and nivolumab. Dr. Noon is a Kauffman Fellow, member of Class 23. He received a PharmD and MBA each from the University of Connecticut.

×
×
×

Venture Partners

John Glasspool

Venture Partner

John Glasspool

Venture Partner

Mr. R. John Glasspool serves as a Venture Partner at Agent Capital, LLC, and has over 25 years of deep commercial industry expertise throughout the BioPharma industry. John was former Executive Vice President and Head of Corporate Strategy & Commercial Operations at Baxalta from 2015 to 2017. He served as Vice President, Head of Emerging Therapies and Market Development of Baxter International’s Bioscience division from 2012 to 2015. From 2002 to 2012, John served at Novartis where he was Head of Region Europe for Vaccines and Diagnosis; Global Head Pharma Commercial Operations, Pricing and Market Access; and Head of Cardiovascular and Neuroscience Franchises. From 1991 to 2002, John served at Johnson & Johnson where he had roles of increasing responsibility within the Sales and Marketing division, including as Director of Strategic Marketing.

×

Bruce Peacock

Venture Partner

Bruce Peacock

Venture Partner

Mr. Bruce A. Peacock, CPA, serves as a Venture Partner at Agent Capital, LLC and as Executive Chairman at Carisma Therapeutics. Bruce has over 35 years of life sciences experience, including senior executive roles at a number of companies with successful exits. From 2010 to 2014, Bruce served as the Chief Financial and Chief Business Officer of Ophthotech Corporation (IPO in 2013). Prior to Ophthotech, Bruce served as President and Co-Chairman of Alba Therapeutics Corporation. Prior to Alba, Bruce served as Chief Executive Officer of The Little Clinic (acquired by Kroger), Adolor Corporation (acquired by Cubist/Merck), and Orthovita (acquired by Stryker). From 1992 to 1999, Bruce served as Executive Vice President and the Chief Operating Officer of Cephalon Inc (acquired by Teva). From 1982 to 1992, he served as a Senior Vice President and the Chief Financial Officer at Centocor Ortho Biotech, Inc. (acquired by Janssen/J&J).

×
×